CN114867485A - Cd38敲除的原代和扩增的人nk细胞的生成 - Google Patents

Cd38敲除的原代和扩增的人nk细胞的生成 Download PDF

Info

Publication number
CN114867485A
CN114867485A CN202080090071.9A CN202080090071A CN114867485A CN 114867485 A CN114867485 A CN 114867485A CN 202080090071 A CN202080090071 A CN 202080090071A CN 114867485 A CN114867485 A CN 114867485A
Authority
CN
China
Prior art keywords
cells
cell
subject
cancer
dara
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080090071.9A
Other languages
English (en)
Chinese (zh)
Inventor
迪恩·安东尼·李
M·N·卡拉鲁迪
G·吉奥
永井雄也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Nationwide Childrens Hospital Inc
Original Assignee
Johns Hopkins University
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Nationwide Childrens Hospital Inc filed Critical Johns Hopkins University
Publication of CN114867485A publication Critical patent/CN114867485A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080090071.9A 2019-10-31 2020-11-02 Cd38敲除的原代和扩增的人nk细胞的生成 Pending CN114867485A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928524P 2019-10-31 2019-10-31
US62/928,524 2019-10-31
PCT/US2020/058565 WO2021087466A1 (en) 2019-10-31 2020-11-02 Generation of cd38 knock-out primary and expanded human nk cells

Publications (1)

Publication Number Publication Date
CN114867485A true CN114867485A (zh) 2022-08-05

Family

ID=75715400

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090071.9A Pending CN114867485A (zh) 2019-10-31 2020-11-02 Cd38敲除的原代和扩增的人nk细胞的生成

Country Status (11)

Country Link
US (1) US20220401482A1 (enExample)
EP (1) EP4051297A4 (enExample)
JP (1) JP2022554284A (enExample)
KR (1) KR20220093337A (enExample)
CN (1) CN114867485A (enExample)
AU (1) AU2020375053A1 (enExample)
BR (1) BR112022008215A2 (enExample)
CA (1) CA3156509A1 (enExample)
IL (1) IL292584A (enExample)
MX (1) MX2022005051A (enExample)
WO (1) WO2021087466A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116679065A (zh) * 2023-07-31 2023-09-01 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
EP4347816A4 (en) * 2021-06-02 2026-04-29 Metagenomi Therapeutics Inc CRISPR CLASS II, TYPE V SYSTEMS
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
US20250302874A1 (en) * 2021-11-03 2025-10-02 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
JP2025001053A (ja) * 2021-11-05 2025-01-08 学校法人東海大学 劇症型ｎｋ白血病に対する治療標的の同定
JP2025509343A (ja) 2022-03-07 2025-04-11 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用
CN114921416B (zh) * 2022-05-12 2023-05-23 广东普罗凯融生物医药科技有限公司 一种nk细胞及其制备方法
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
WO2024124244A1 (en) * 2022-12-09 2024-06-13 Research Institute At Nationwide Children's Hospital Cd38 as integration site for enhanced function of gene-modified immune cells
WO2024124242A2 (en) * 2022-12-09 2024-06-13 Research Institute At Nationwide Children's Hospital Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies
WO2024155711A1 (en) * 2023-01-17 2024-07-25 Research Institute At Nationwide Children's Hospital Methods of targeting glycogen synthase kinase 3 beta in nk cells
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
WO2026050706A1 (en) * 2024-08-30 2026-03-05 Aventis Inc. Nk cells having reduced cd38 expression and method for producing

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
US20180171298A1 (en) * 2015-06-30 2018-06-21 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US20180208669A1 (en) * 2014-06-16 2018-07-26 The United States of America, as represented by th e Secretary, Dept. of Health and Human Services BLOCKING CD38 USING ANTI-CD38 F(ab')2 TO PROTECT NK CELLS
WO2019126748A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
US20190201442A1 (en) * 2015-07-15 2019-07-04 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
CN110248669A (zh) * 2016-12-09 2019-09-17 昂克免疫有限公司 工程化天然杀伤细胞及其用途
US20190282618A1 (en) * 2016-01-20 2019-09-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US128A (en) 1837-02-16 Holdback for sleds
FR1601438A (enExample) 1968-10-17 1970-08-24
CA2926078C (en) * 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
CA3020330A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180208669A1 (en) * 2014-06-16 2018-07-26 The United States of America, as represented by th e Secretary, Dept. of Health and Human Services BLOCKING CD38 USING ANTI-CD38 F(ab')2 TO PROTECT NK CELLS
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
US20180171298A1 (en) * 2015-06-30 2018-06-21 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US20190201442A1 (en) * 2015-07-15 2019-07-04 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US20190282618A1 (en) * 2016-01-20 2019-09-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN110248669A (zh) * 2016-12-09 2019-09-17 昂克免疫有限公司 工程化天然杀伤细胞及其用途
WO2019126748A1 (en) * 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
CN113518826A (zh) * 2018-05-16 2021-10-19 全国儿童医院研究所 利用cas9核糖核蛋白来产生敲除的原代和扩增的人nk细胞

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116679065A (zh) * 2023-07-31 2023-09-01 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Also Published As

Publication number Publication date
KR20220093337A (ko) 2022-07-05
IL292584A (en) 2022-06-01
CA3156509A1 (en) 2021-05-06
MX2022005051A (es) 2022-08-08
EP4051297A4 (en) 2023-10-18
AU2020375053A1 (en) 2022-05-26
EP4051297A1 (en) 2022-09-07
US20220401482A1 (en) 2022-12-22
JP2022554284A (ja) 2022-12-28
WO2021087466A1 (en) 2021-05-06
BR112022008215A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
US20220401482A1 (en) Generation of cd38 knock-out primary and expanded human nk cells
JP7101419B2 (ja) 内因性ｔ細胞受容体の標的置換
US20220105133A1 (en) Tumor infiltrating lymphocytes and methods of therapy
Sasidharan Nair et al. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner
JP2025078701A (ja) 標的化された非ウイルスｄｎａ挿入
KR102846479B1 (ko) Cas9 리보핵단백질을 사용하는 녹아웃 일차 및 확장된 인간 nk 세포의 생성
Nair et al. Down-regulation of Tet2 prevents TSDR demethylation in IL2 deficient regulatory T cells
Vago et al. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia
JP2018518181A (ja) 血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体
US11786550B2 (en) gRNA targeting HPK1 and a method for editing HPK1 gene
US12540311B2 (en) Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients
Gallouet et al. Macrophage production and activation are dependent on TRIM33
JP2021524233A (ja) 薬物耐性免疫細胞及びその用途
WO2020139873A1 (en) Tollip deficient neutrophils and uses thereof
JP2022553855A (ja) 長さが２１～３０ヌクレオチドのガイド配列を使用したヘテロ接合ｅｌａｎｅ遺伝子の対立遺伝子のさまざまなノックアウト
KR20250075587A (ko) T 세포 조작을 개선하기 위한 유전독성 스트레스의 억제
RU2808035C2 (ru) Образование нокаутных первичных и размноженных nk-клеток человека с использованием рибонуклеопротеинов cas9
IL321991A (en) Cell context-specific gene regulation using inhibitory RNAs
Lam et al. Optimized CRISPR-mediated gene knock-in reveals FOXP3-independent control of human Treg identity
EA049987B1 (ru) Прицельная безвирусная вставка днк

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination